The Claim as It Circulates
The version you encounter on forums and vendor pages goes roughly like this:
BPC-157 is stable in gastric acid because it was originally isolated from gastric juice
Proteases can’t degrade it for the same reason
Intact peptide reaches systemic circulation after oral dosing
Injections are therefore unnecessary for people who want systemic effects
The framing is confident, the mechanism sounds plausible on first read, and it gets repeated often enough that it starts to feel established.
The confidence is borrowed from findings that don’t support the conclusion being drawn.
Where the Myth Originates
The primary source material is a long series of rodent studies from Sikiric and colleagues, running from the 1990s through the present, showing that orally administered BPC-157 produces measurable healing in gastrointestinal tissue. A 2025 literature and patent review confirms that BPC-157 has demonstrated pleiotropic beneficial effects across preclinical models, including inflammatory bowel disease and other gastrointestinal conditions, while noting that no regulatory body has approved it due to insufficient human clinical evidence. [1] That review is representative of the overall literature: real preclinical signals, real absence of clinical translation.
The leap from “oral dosing heals gut tissue in rats” to “oral dosing achieves systemic bioavailability” is something commentators and vendors made, not something the original researchers established. The original studies didn’t include plasma pharmacokinetic measurements, so they couldn’t have supported the systemic absorption claim even if the authors had wanted to make it.
On the question of whether BPC-157’s origin in gastric juice means it must be stable there in a pharmacologically useful way: the evidence for this specific claim is thin. The name “Body Protection Compound” and the gastric juice origin story have been used to imply the peptide is native to the gut environment and therefore inherently resistant to degradation, a marketing inference, not a pharmacological one. No published stability data demonstrate that BPC-157 resists luminal protease activity at the concentrations and conditions relevant to oral dosing.
The gap in human pharmacokinetic data is real, but it’s a gap in the record, not a documented negative result. Citing that absence as a verified finding requires more than the current literature provides.
What the Literature Shows
The general pharmacology of therapeutic peptides is well characterized. Peptides are subject to rapid hydrolysis by luminal proteasesincluding:
Pepsin in the stomach
Trypsin and chymotrypsin in the small intestine
Degradation by the acidic pH of the gastric environment
A 2025 review on oral peptide delivery documents that this proteolytic and pH-related degradation is the central barrier to oral bioavailability for therapeutic peptides as a class, leading to poor systemic exposure across the board. [2] That review doesn’t address BPC-157 specifically, but the physicochemical problem it describes applies to a 15-amino-acid peptide without any known modification conferring protease resistance.
For systemic effects at sites remote from the gut, the picture is more complicated. A 2021 rat study in Frontiers in Pharmacology reports that BPC-157 promotes healing across multiple tissue types, including tendon, ligament, muscle, bone, and nerve, via multiple routes of administration at equivalent dose ranges, with mechanisms involving vascular and coagulation pathways. [3]
The study doesn’t report plasma pharmacokinetic data, so it can’t confirm whether the mechanism for oral dosing is systemic absorption of intact peptide or something else. The finding that different routes produce comparable effects is genuinely interesting, but it’s also consistent with a gut-mediated signaling mechanism rather than conventional oral bioavailability. Without plasma concentration measurements, you can’t distinguish between those two explanations.
No published human pharmacokinetic studies have measured BPC-157 plasma levels after oral administration, and no human clinical trial has used oral dosing as the primary route in a controlled design. This isn’t a regulatory technicality; it means the foundational measurement required to support the oral bioavailability claim simply hasn’t been done.
The Kernel of Truth
The oral efficacy data in rodent GI models is real and reproducible. A 2024 review in Pharmaceuticals discusses BPC-157’s cytoprotective activity and its stability in human gastric juice, along with interactions across multiple neurotransmitter systems, consistent with a substantial body of preclinical evidence. [4]
Orally administered BPC-157 produces statistically significant healing of gastric ulcers, colitis lesions, and intestinal anastomoses in controlled rat studies compared to vehicle. That’s a legitimate finding, and it’s worth taking seriously for GI-specific applications.
The most defensible interpretation is that the peptide has local luminal or mucosal activity: it reaches the mucosal surface intact at concentrations sufficient to produce a biological effect, even if it doesn’t cross the epithelium into systemic circulation in meaningful amounts. Local luminal bioavailability and systemic bioavailability measure different things, and the GI healing data supports the former without establishing the latter.
Some researchers have also proposed that BPC-157 acts through enteric nervous system pathways or gut-brain signaling. A 2020 rat study on hippocampal ischemia/reperfusion injury references BPC-157’s proposed role as a mediator of cytoprotection and bidirectional effects in the gut-brain axis as background context, while demonstrating neuroprotective effects via local application. [5] The gut-brain axis framing would explain apparent remote effects without requiring intact peptide to enter systemic circulation. It remains a proposed mechanism rather than a demonstrated one, but it’s pharmacologically coherent in a way that “oral bioavailability equals injectable bioavailability” is not.
Why the Myth Persists
Vendors selling oral capsules have an obvious reason to present local GI efficacy data as evidence of systemic bioavailability. If the honest framing is that oral BPC-157 probably works locally in the gut and may or may not produce systemic effects through indirect signaling, the compound’s perceived utility for tendon repair, muscle healing, or neurological applications becomes much harder to argue.
The mechanistic plausibility argumentthat a peptide found in gastric juice must be acid-stable and therefore bioavailable, conflates two separate physiological problems. Surviving in gastric juice as an endogenous secretion is not the same as surviving luminal protease activity at the concentrations present during active digestion and then crossing the intestinal epithelium intact in therapeutically relevant amounts. Those are distinct barriers, and clearing the first doesn’t imply clearing the second or third.
Anecdotal reports of systemic effects after oral dosing are also genuinely hard to evaluate, because BPC-157’s proposed mechanisms, including nitric oxide pathway modulation and growth factor upregulation, are diffuse enough that a wide range of subjective improvements can be attributed to them. That’s not a reason to dismiss anecdotes entirely, but it’s a reason not to treat them as pharmacokinetic evidence.
The Defensible Position
A 2022 animal study in Biomedicines reviewing BPC-157’s cardioprotective and cytoprotective effects via multiple molecular pathways confirms the breadth of the preclinical signal while not addressing pharmacokinetic comparisons between oral and parenteral routes. [6] That pattern, strong preclinical signal with no route-comparison pharmacokinetics, runs through the BPC-157 literature consistently.
Oral BPC-157 has credible, reproducible efficacy for gastrointestinal tissue in rodent models, and that finding is worth taking seriously for GI-specific applications. The extrapolation to systemic bioavailability equivalent to parenteral administration is not supported by any published pharmacokinetic data in any species.
Bottom line: Until plasma concentration data following oral dosing are published, the claim that oral and injectable BPC-157 produce equivalent systemic exposure should be treated as an untested hypothesis. For indications beyond the gastrointestinal tract, parenteral administration has a stronger pharmacological rationale, because at least with injection you know the peptide reaches systemic circulation. With oral dosing, you’re assuming it does. That assumption hasn’t been tested with the methodology required to confirm it, and given what’s known about peptide degradation in the gut, the assumption is probably wrong.
References
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.. Pharmaceuticals (Basel, Switzerland), 2025.
Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms.. Biomedicines, 2025.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.. Frontiers in pharmacology, 2021.
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.. Pharmaceuticals (Basel, Switzerland), 2024.
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats.. Brain and behavior, 2020.